Phibro Animal Health (PAHC) Receivables (2013 - 2026)

Phibro Animal Health's Receivables history runs 14 years deep, the most recent figure standing at $221.5 million for Q1 2026.

• On a quarterly basis, Receivables rose 12.16% year-over-year to $221.5 million in Q1 2026; TTM through Mar 2026 was $221.5 million, a 12.16% increase from a year earlier, with the FY2025 full-year figure at $228.0 million, up 34.54% from the prior year.
• Receivables advanced to $221.5 million in Q1 2026 per PAHC's latest filing, from $215.9 million in the prior quarter.
• Across five years, Receivables topped out at $228.0 million in Q2 2025 and bottomed at $142.7 million in Q3 2022.
• The 5-year median for Receivables is $165.1 million (2023), against an average of $176.6 million.
• Across the five-year window, Receivables retreated 2.93% in 2023 and soared 35.53% in 2025, its largest moves.
• Year by year, Receivables stood at $151.8 million in 2022, then fell by 0.79% to $150.6 million in 2023, then increased by 27.33% to $191.8 million in 2024, then grew by 12.56% to $215.9 million in 2025, then advanced by 2.63% to $221.5 million in 2026.
• Per Business Quant, the three latest PAHC Receivables figures stand at $221.5 million (Q1 2026), $215.9 million (Q4 2025), and $217.9 million (Q3 2025).